AstraZeneca to Partner with VaxEquity in Imperial Self-Amplifying RNA Technology

Astra Zeneca

The multinational pharmaceutical and biotechnology company made a deal with the firm behind Imperial College London’s experimental Covid-19 vaccine to develop and sell drugs on its self-amplifying RNA technology.

AstraZeneca will make a “sizeable” investment in the company called VaxEquity, and provide milestone payments of as much as $195 million, and funding as many as 26 drug targets. Both the company’s plans to develop both therapies and vaccines, using self-amplifying RNA.

“We have had interest from other pharma partners, but I think what is interesting for us in terms of AstraZeneca is their wider interest in exploiting this technology, not just in the infectious disease space,” -Robin Shattock, the professor leading the research at Imperial, said.

This collaborative technology will work in the same way as the messenger RNA (mRNA) made by Pfizer-BioNTech and Moderna.

We believe self-amplifying RNA, once optimized, will allow us to target novel pathways not amenable to traditional drug discovery across our therapy areas of interest,” – said AstraZeneca research chief Mene Pangalos.

No Comments Yet

Comments are closed


CIO Look is Global business authority platform where you can explore the perspective of Entrepreneurs, business owners, and innovators who drive business around the globe. CIOLook has unvaryingly been at the front line for its honesty and genuineness acquiring acknowledgment from Business pioneers universally. It features best business hones inferred by individuals, organizations, and industry divisions around the globe…. Read More

Follow us